A full read of the healthcare market heading into renewal season, for the people who carry it on the P&L — curated to your chair, scaled to your plan. No script. No pitch. Your renewal is already being priced.
Take the company's annual cost for medical + pharmacy — what the business actually pays after employee payroll contributions come out. Divide by your enrolled employees. That's PEPY (per employee per year). Divide by 12 and you have PEPM. It's on your renewal workbook, or your controller can pull it from the GL in about five minutes.
Figures scale from your employer-net cost per employee at an ~8% trend — directional, not a quote. Pick a range or enter your exact PEPM, and every dollar figure below reflects your number.
The largest variable expense on your P&L is also the one the market won't correct for you. Three forces push that cost toward your renewal. A set of levers pushes back. And the window to pull them closes before the renewal arrives. Most leaders meet that as a surprise. It isn't one — here's the map.
Commercial insurance just turned soft after the longest hard market since the 1980s. Health doesn't turn. It compounds — on a line two-to-four times larger.
Government underpayment, an arbitration system off by 280×, a pharmacy pipeline the formulary can't absorb, and a new wave of fiduciary lawsuits. Four forces, one direction.
Net pharmacy cost, the GLP-1 channel, reading your own claims before the carrier does, the pool you're standing in, and the calendar. Together they bend the curve — the other way.
Every dollar trend eats is a dollar that didn't hire, didn't retain, didn't fall to margin. The capital it consumes, and the people you can't replace.
Commercial insurance cycles. Healthcare compounds. The market eventually corrects one. It does not correct the other.
Pick the chair that’s yours — the whole read re-curates to it: which sections are “one of yours,” the lens on each Movement, the questions that build your exposure map. Not sure? Keep flying — you can switch any time from the menu up top.
Property & casualty broke its twenty-seven-quarter climb and turned negative in early 2025 — the way cycles do. Employer health kept compounding straight through it. Same economy, same six years. After the cross point, one line bends down on its own. The other keeps climbing onto a line two-to-four times larger.
Sources: MarshMarsh Global Insurance Market Index Q1 2025 — commercial P&C turned negative early 2025. · CIAB Commercial P/C Index · KFF 2025 · Mercer/Aon 2026. At an 8% trend, healthcare cost doubles every 9 years; P&C at ~1.5% doubles every 47.
Are you still managing your health line the way you manage the lines that cycle — waiting it out?
The No Surprises Act routed out-of-network billing fights to arbitration in 2022. Federal officials modeled the volume before launch — about seventeen thousand disputes a year. Put the forecast next to reality and the scale tells the story. Every one of those repriced claims has to land somewhere. It lands inside next year's premium.
Sources: Health Affairs / Georgetown CHIRHealth Affairs & Georgetown Center on Health Insurance Reforms analysis of CMS IDR data, 2025. · CMS No Surprises Act IDR reports. Providers win ~88% of resolved cases at ~8.9× the insurer benchmark.
How much of your last three renewals was arbitration premium — a cost you never voted for, that the letter never named?
Pharmacy trend is running 11–12% — well above the ~8.5% medical trend — and it accelerates from here. The plan designs that absorb the 2027–2028 wave are set long before the drug shows up on a claims report. By the time a $3M therapy lands, the design that pays for it is already in place. Or it isn't.
Oral weight-loss GLP-1s broaden prescribing; direct-to-employer channels go live. Category projected past $130B globally by 2030.
Dozens of cell & gene approvals a year. Single treatments $2–4.25M — price points where rebate math no longer applies.
Specialty passes ~55–60% of total pharmacy spend. The biosimilar offset can't keep pace with reference-drug economics.
Was your pharmacy strategy built for the drugs on last year’s claims report — or the ones the 2027–2028 pipeline is about to deliver?
A rebate is not a discount. It's a placement fee — a payment a manufacturer makes to a PBM for favorable formulary position. The drug with the largest rebate wins the position, and it's almost always the most expensive drug on your plan. Same drug class, two options. Tap the one you think costs the plan less.
Do you know your plan's true net pharmacy cost — not gross spend, not rebate income, but the single auditable figure after every upstream deduction?
"Cover it or cut it" was never the real choice. The real question is which channel the drug travels through — a plan-design decision, not a coverage surrender. Same medication, same member, a fraction of the exposure. Switch the path.
Lilly Connect offers Zepbound at $449/mo direct-to-employer; cash channels (NovoCare, TrumpRx) run $149–449/mo. Same drug — it just never enters the channel that marks it up. New programs; terms move quarter to quarter, and the carve-out has to be structured correctly.
Your people are going to get these drugs one way or another. Is your plan paying the channel that marks them up — or the one that doesn’t?
Moving off fully-insured means trading a fixed, predictable number for a variable one you now own. You keep the good years. You also own the bad months. The flat line is what you buy today. The jagged line is what self-funding feels like — and the bad month arrives first, weeks before stop-loss reimburses.
A normal month near $167K can spike past $400K+ — paid from operating cash, weeks before stop-loss reimburses. You're buying a better average by accepting a worse worst-month.
If your plan had its worst month next quarter, do you know what would leave the account before stop-loss paid you back?
A dollar absorbed by trend is a dollar that didn't fund a hire, open a territory, replace equipment, or fall through to margin. At 8% compounding on the second-largest line of the P&L, that isn't a benefits decision. It's a capital-allocation decision the company makes by default — every renewal, without ever framing it as one.
About $2.7M of cash drawn along the way, none of it ever put to a decision. Below the operating line it concentrates: in a business valued on a multiple of EBITDA, every recurring avoidable dollar is multiplied against enterprise value.
Has the team that pays for the plan ever framed the trend as a capital-allocation decision — or does it just happen at renewal?
There's a line item that never appears on your P&L, because no one bills you for it — and it isn't happening after hours. It's the call to a parent's specialist, the hold music with a hospital three states away. The person who ends up managing a family's crisis is usually the same person managing the most at work. The load doesn't spread evenly. It concentrates on the people already carrying the most.
Which of your people could you not afford to lose — and what's keeping them that a competitor couldn't undo with one phone call?
Left alone, this cost compounds and the market won't correct it. So the work has two jobs, in order: reduce the number now — wring out the spending that buys no health — then hold it flat while the trend pulls back. Every move serves one of those jobs. None is a teardown.
Illustrative mechanism, not a forecast. Baseline holds the read's 8% trend; the gold path shows the shape the moves are built to produce — a year-one reduction, then a held line. Endpoints scale with your plan.
Does your plan get watched year-round like any compounding line — or opened once a year at renewal?
Most plans need three or four tailored moves — and the leverage to make them exists before the renewal does, not after. This isn't a quote and it isn't a pitch. It's a walk through your plan, line by line, the way a CFO walks a P&L. Some plans don't have much sitting unused. If yours is one of them, you'll know inside twenty minutes — and we'll both move on.